NUVECTIS PHARMA INC NVCT
COM · Common Stock · CUSIP 67080T108
- SectorHealth care
- IndustryPharmaceutical Preparations
- HeadquartersFort Lee, NJ
- FilingsSEC EDGAR
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable. Shares outstanding: 14.6m as of 2022-08-04, from the company's own SEC filing; the percentage can still exceed 100%: lent-out shares are counted by the lender and the buyer, and some reports overlap without saying so. Implied quarter-end price ≈ $11.20.
Trends to Q2 2022
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q1 2022 | 9 |
| Q2 2022 | 12 |
Biggest buyers
| BALDWIN WEALTH PARTNERS LLC/MA | New | +121.0k |
| CITADEL ADVISORS LLC | New | +35.1k |
| VANGUARD GROUP INC | New | +23.3k |
| STATE STREET CORP | New | +11.7k |
| GEODE CAPITAL MANAGEMENT, LLC | Added | +9.1k |
| MORGAN STANLEY | New | +200 |
| WELLS FARGO & COMPANY/MN | Added | +1 |
Biggest sellers
| Ronit Capital LLP | Reduced | -130.7k |
| MILLENNIUM MANAGEMENT LLC | Sold out | -42.2k |
| Virtu Financial LLC | Sold out | -11.4k |
| BlackRock Inc. | Reduced | -674 |
| Tower Research Capital LLC (TRC) | Reduced | -471 |
| UBS Group AG | Reduced | -79 |
Major shareholders (over 5%)
Anyone who owns more than 5% of a class of the company's shares has to say so: on Schedule 13D if they may try to influence or control the company, on 13G if they're a passive investor, and update it as the stake changes. Each holder's latest filing, from 19 Dec 2024 on; percentages are of the share class, as the holder worked them out.
| Holder | Stake |
|---|---|
| Soleus Private Equity Fund III, L.P. 13G · passive investor new · filed 2026-08-06 | 5.1% |
Insider purchases and sales in Q2 2022
Shares bought or sold by the company's own officers, directors and 10% owners, in the open market or privately, as they reported to the SEC on Form 4 (due within two business days of the trade). Grants, option exercises, shares withheld for tax and gifts aren't included.
Officers and directors buying vs selling
Number of people, by quarter (10% owners not included)
Numbers
| Quarter | Buying | Bought | Selling | Sold | Sold under a plan |
|---|---|---|---|---|---|
| Q3 2020 | 0 | — | 0 | — | — |
| Q4 2020 | 0 | — | 0 | — | — |
| Q1 2021 | 0 | — | 0 | — | — |
| Q2 2021 | 0 | — | 0 | — | — |
| Q3 2021 | 0 | — | 0 | — | — |
| Q4 2021 | 0 | — | 0 | — | — |
| Q1 2022 | 3 | $1.4m | 0 | — | — |
| Q2 2022 | 5 | $565.3k | 0 | — | — |
| Date | Insider | Trade | Value |
|---|---|---|---|
| 2022-06-29 | BENTSUR RON Chairman & CEO, director | Bought | $43.0k3.7k shares |
| 2022-06-28 | BENTSUR RON Chairman & CEO, director | Bought | $3.5k300 shares |
| 2022-06-24 | BENTSUR RON Chairman & CEO, director | Bought | $4.9k400 shares |
| 2022-06-23 | BENTSUR RON Chairman & CEO, director | Bought | $2.3k200 shares |
| 2022-06-22 | BENTSUR RON Chairman & CEO, director | Bought | $1.3k100 shares |
| 2022-05-27 | BENTSUR RON Chairman & CEO, director | Bought | $7.9k500 shares |
| 2022-05-26 | BENTSUR RON Chairman & CEO, director | Bought | $8.0k500 shares |
| 2022-05-20 | BENTSUR RON Chairman & CEO, director | Bought | $16.3k1.0k shares |
| 2022-05-20 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $5.0k300 shares |
| 2022-05-19 | BENTSUR RON Chairman & CEO, director | Bought | $3.8k200 shares |
| 2022-05-18 | BENTSUR RON Chairman & CEO, director | Bought | $32.9k1.7k shares |
| 2022-05-17 | BENTSUR RON Chairman & CEO, director | Bought | $6.2k310 shares |
| 2022-05-17 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $2.8k142 shares |
| 2022-05-16 | BENTSUR RON Chairman & CEO, director | Bought | $19.3k1.0k shares |
| 2022-05-16 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $1.9k100 shares |
| 2022-05-13 | BENTSUR RON Chairman & CEO, director | Bought | $12.7k700 shares |
| 2022-05-12 | BENTSUR RON Chairman & CEO, director | Bought | $208.0k12.2k shares |
| 2022-05-12 | Hoberman Kenneth Director | Bought | $104.4k6.0k shares |
| 2022-05-12 | Kaplan Matthew L. Director | Bought | $50.6k3.0k shares |
| 2022-05-12 | Shemesh Shay Chief Dev. & Ops. Officer | Bought | $20.3k1.3k shares |
| 2022-05-12 | Poradosu Enrique Chief Science & Business Off | Bought | $10.3k670 shares |
Their holding: how much the trade added to or took from the insider's holding (direct, or the trust or fund named). The same trade is sometimes reported by more than one insider, such as a fund and the director who represents it; totals count it once. A value is left blank where the reported price is far from the market price (usually a typo).
Holders, Q2 2022
| Manager | Shares | Change |
|---|---|---|
| Ronit Capital LLP 6.66% of their portfolio | 419.3k $4.7m | Reduced -130.7k |
| BALDWIN WEALTH PARTNERS LLC/MA 0.18% of their portfolio | 121.0k $1.4m | New |
| CITADEL ADVISORS LLC 0.00% of their portfolio | 35.1k $393.0k | New |
| GEODE CAPITAL MANAGEMENT, LLC 0.00% of their portfolio | 24.0k $268.0k | Added +9.1k |
| VANGUARD GROUP INC 0.00% of their portfolio | 23.3k $261.0k | New |
| STATE STREET CORP 0.00% of their portfolio | 11.7k $131.0k | New |
| BlackRock Inc. 0.00% of their portfolio | 7.2k $80.0k | Reduced -674 |
| Tower Research Capital LLC (TRC) 0.00% of their portfolio | 1.3k $14.0k | Reduced -471 |
| MORGAN STANLEY 0.00% of their portfolio | 200 $2.0k | New |
| UBS Group AG 0.00% of their portfolio | 62 $1.0k | Reduced -79 |
| WELLS FARGO & COMPANY/MN 0.00% of their portfolio | 21 $0 | Added +1 |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0.00% of their portfolio | 0 $0 | Unchanged |